Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study

Documenti analoghi

• Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV : Data from the COMBINE ‐2 study
  di: Cristina Mussini, et al.
  Pubblicazione: (2026)
• Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study
  di: Ricky K. Hsu, et al.
  Pubblicazione: (2025)
• Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
  di: Inés Suárez‐García, et al.
  Pubblicazione: (2025)
• Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV
  di: Maria Saumoy, et al.
  Pubblicazione: (2025)
• Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study
  di: M. Gartland, et al.
  Pubblicazione: (2025)